Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors

British Journal of Anaesthesia

Volumn 89, Issue 6, 2002, Pages 882-887

  Jerman, J C ^a   Gray, J ^a   Brough, S J ^a   Ooi, L ^a   Owen, D ^a   Davis, J B ^a   Smart, D ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Analgesics non opoid, anandamide; Equipment, flurometric imaging plate reader; Receptors, cannabinoid; Receptors, vanilloid; Spinal cord, dorsal root ganglion

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CALCIUM; CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; CAPSAZEPINE; DEXANABINOL; LIGAND; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; OLVANIL; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CELL CLONE; CELL TYPE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVICE; DORSAL ROOT; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMAGING; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPINAL GANGLION;

EID: 0036899448     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aef281     Document Type: Article

References (25)

1. Devane WA, Dysarz FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13
2. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5
3. 2 receptors. Pharmacol Ther 1997; 74: 129-80
4. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9
5. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 5O: 83-90
6. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97
7. Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 1998; 284: 1209-17
8. 2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75: 2434-44
9. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999; 51: 159-212
10. Smart D, Gunthorpe MJ, Jerman JC, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVRI). Br J Pharmacolol 2000; 129: 227-30
11. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7
12. Jerman JC, Brough SJ, Prinjha R, et al. Characterization using FLIPR of rat vanilloid receptor (rVRI) pharmacology. Br J Pharmacolol 2000; 130: 916-22
13. Skaper SD, Facci L, Milani D. Culture and use of primary and clonal neuronal cells. In: Conn PM, ed. Methods in Neurosciences, Vol. 2. San Diego: Academic Press, 1990; 17-33
14. 1 using the fluometric imaging plate reader (FLIPR). In: Lambert DG, ed. Calcium Signaling Protocols. New Jersey: Humana Press, 1999; 125-136
15. Bowen WP, Jerman JC. Nonlinear regression using spreadsheets. Trends Pharmacol Sci 1995; 16: 413-7
16. 50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108
17. Lan R, Liu Q, Fan P, et al. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 1999; 42: 769-76
18. Huffman JW, Lainton JAH. Recent developments in the medicinal chemistry of cannabinoids. Curr Med Chem 1996; 3: 101-16
19. Jerman JC, Brough SJ, Davis JB, et al. The endogenous lipid anandamide is an agonist at rat and human vanilloid (VRI) receptors. Eur J Neurosci 2000; 12 (Suppl. II): 59.10
20. Ahluwalia J, Urban L, Capogna M, et al. Cannabinoid I receptors are expressed in nociceptive primary sensory neurons. Neuroscience 2000; 100: 685-8
21. Jung YS, Cho TS, Moon CH, et al. Capsaicin-induced desensitization is prevented by capsazepine but not by ruthenium red in guinea pig bronchi. Eur J Pharmacol 1998; 362: 193-8
22. Zygmunt PM, Julius I, Di Marzo I, et al. Anandamide - the other side of the coin. Trends Pharmacol Sci 2000; 21: 43-4
23. Smart D, Jerman JC. Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol Sci 2000; 21: 134
24. Szolcsanyi J. Anandamide and the question of its functional role for activation of capsaicin receptors. Trends Pharmacol Sci 2000; 21: 203-4
25. Di Marzo V, Bisogno T, De Petrocellis L. Endocannabinoids: new targets for drug development. Curr Pharmaceutical Des 2000; 6: 1361-80